Jorge A. Quiroz

Palle Juul Jensens Boulevard 82
Aarhus N, 8200, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Neuromuscular junction failure in sarcopenia is linked to NaV1.4 loss and reversed by ClC-1 inhibition.

Neuromuscular junction failure in sarcopenia is linked to NaV1.4 loss and reversed by ClC-1 inhibition.

Journal: The Journal of clinical investigation

Published: July 09, 2026

Neuromuscular junction failure in sarcopenia is linked to NaV1.4 loss and reversed by ClC-1 inhibition.

Neuromuscular junction failure in sarcopenia is linked to NaV1.4 loss and reversed by ClC-1 inhibition.

Journal: The Journal of clinical investigation

Published: January 27, 2025

Neuromuscular transmission deficits in patients with CMT and ClC-1 inhibition in CMT animal models.

Neuromuscular transmission deficits in patients with CMT and ClC-1 inhibition in CMT animal models.

Journal: Annals of clinical and translational neurology

Published: September 18, 2024

The ClC-1 chloride channel inhibitor NMD670 improves skeletal muscle function in rat models and patients with myasthenia gravis.

The ClC-1 chloride channel inhibitor NMD670 improves skeletal muscle function in rat models and patients with myasthenia gravis.

Journal: Science translational medicine

Published: March 20, 2024

Safety, Pharmacokinetics, and Pharmacodynamics of a First-in-Class ClC-1 Inhibitor to Enhance Muscle Excitability: Phase I Randomized Controlled Trial.

Safety, Pharmacokinetics, and Pharmacodynamics of a First-in-Class ClC-1 Inhibitor to Enhance Muscle Excitability: Phase I Randomized Controlled Trial.

Journal: Clinical pharmacology and therapeutics

Published: February 22, 2024

Validation of an ambient measurement system (AMS) for physical activities in a paediatric population.

Validation of an ambient measurement system (AMS) for physical activities in a paediatric population.

Journal: Journal of medical engineering & technology

Published: July 16, 2019

Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression.

Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression.

Journal: Nature genetics

Published: July 28, 2017

Effect of the mGluR5-NAM Basimglurant on Behavior in Adolescents and Adults with Fragile X Syndrome in a Randomized, Double-Blind, Placebo-Controlled Trial: FragXis Phase 2 Results.

Effect of the mGluR5-NAM Basimglurant on Behavior in Adolescents and Adults with Fragile X Syndrome in a Randomized, Double-Blind, Placebo-Controlled Trial: FragXis Phase 2 Results.

Journal: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology

Published: March 13, 2017

An Analysis of Two Genome-wide Association Meta-analyses Identifies a New Locus for Broad Depression Phenotype.

An Analysis of Two Genome-wide Association Meta-analyses Identifies a New Locus for Broad Depression Phenotype.

Journal: Biological psychiatry

Published: August 03, 2016

Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression: A Randomized Clinical Trial.

Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression: A Randomized Clinical Trial.

Journal: JAMA psychiatry

Published: June 16, 2016

Caregiver Preferences for the Treatment of Males with Fragile X Syndrome.

Caregiver Preferences for the Treatment of Males with Fragile X Syndrome.

Journal: Journal of developmental and behavioral pediatrics : JDBP

Published: November 24, 2015

Risk management for moisture related effects in dry manufacturing processes: a statistical approach.

Risk management for moisture related effects in dry manufacturing processes: a statistical approach.

Journal: Pharmaceutical development and technology

Published: November 12, 2014

Showing 1-12 of 12

Last Updated: 09/26/2026